Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling
- 22 November 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in AAPS PharmSciTech
- Vol. 23 (1), 1-13
- https://doi.org/10.1208/s12249-021-02168-7
Abstract
Abiraterone acetate has very low bioavailability and drastic food effect to warrant a dosing regimen under fasting state only. Therefore, we aimed to develop and optimize a liquisolid compact formulation of abiraterone acetate to improve biopharmaceutical attributes aided by pharmacokinetic modelling and achieve dose reduction with no food effect on the formulation. Preliminary studies highlighted the importance of the selection of olive oil as a compatible vehicle. The pharmacokinetic model, integrated with gastrointestinal physiology, was used to predict fasted and fed state pharmacokinetic parameters. Optimization of the liquisolid formulation containing abiraterone acetate was carried at more than five times lower dose, i.e. 190 mg, compared to 1000 mg. A central composite design (CCD) was used to identify optimal levels of formulation factors, namely the amount of vehicle (olive oil), the amount of coating agent (silicon dioxide), and the amount of surfactant (polysorbate 80). Graphical optimization using the selected models in conjunction with maximization of the desirability was used to identify the optimized liquisolid formulation. The predicted pharmacokinetic parameters (fasted Cmax 901.83 ng/mL, fasted AUCinf 2723.82 ng·h/mL, fed Cmax 1024.34 ng/mL, and fed AUCinf 3041.83 ng·h/mL) of the optimized formulation were acceptable. Overall, the liquisolid compact formulation of abiraterone acetate was successfully developed and optimized. In vitro solubility and dissolution results aided by pharmacokinetic modelling also showed improved predicted bioavailability with greater than five times reduction in dose and elimination of food effect.Keywords
This publication has 30 references indexed in Scilit:
- Drug Solubility: Importance and Enhancement TechniquesISRN Pharmaceutics, 2012
- Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy menCancer Chemotherapy and Pharmacology, 2012
- Evaluation of amorphous solid dispersion properties using thermal analysis techniquesAdvanced Drug Delivery Reviews, 2012
- Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancerDrug Design, Development and Therapy, 2012
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole TherapyJournal of Clinical Oncology, 2010
- Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modelingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An UpdatePharmaceutical Research, 2008
- Improving drug solubility for oral delivery using solid dispersionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000